GERRATANA, Lorenzo
 Distribuzione geografica
Continente #
NA - Nord America 4.727
EU - Europa 1.115
AS - Asia 750
SA - Sud America 23
AF - Africa 9
Continente sconosciuto - Info sul continente non disponibili 3
OC - Oceania 1
Totale 6.628
Nazione #
US - Stati Uniti d'America 4.710
SG - Singapore 320
IT - Italia 287
CN - Cina 227
RU - Federazione Russa 183
UA - Ucraina 167
DE - Germania 130
IE - Irlanda 78
IN - India 71
VN - Vietnam 65
SE - Svezia 41
FI - Finlandia 37
GB - Regno Unito 33
BE - Belgio 32
TR - Turchia 31
CZ - Repubblica Ceca 29
AT - Austria 19
BR - Brasile 18
CH - Svizzera 15
CA - Canada 14
NL - Olanda 14
RO - Romania 13
IR - Iran 10
FR - Francia 9
PL - Polonia 7
JP - Giappone 6
HK - Hong Kong 5
EE - Estonia 4
LT - Lituania 4
TG - Togo 4
AR - Argentina 3
EG - Egitto 3
EU - Europa 3
AE - Emirati Arabi Uniti 2
BG - Bulgaria 2
DK - Danimarca 2
ES - Italia 2
IL - Israele 2
LA - Repubblica Popolare Democratica del Laos 2
LV - Lettonia 2
MX - Messico 2
AL - Albania 1
AM - Armenia 1
AU - Australia 1
AZ - Azerbaigian 1
BD - Bangladesh 1
BO - Bolivia 1
BY - Bielorussia 1
CM - Camerun 1
CO - Colombia 1
GE - Georgia 1
IQ - Iraq 1
KG - Kirghizistan 1
KR - Corea 1
LU - Lussemburgo 1
MN - Mongolia 1
NG - Nigeria 1
PA - Panama 1
PT - Portogallo 1
RS - Serbia 1
SA - Arabia Saudita 1
Totale 6.628
Città #
Fairfield 716
Ashburn 490
Chandler 446
Woodbridge 346
Seattle 300
Singapore 278
Houston 262
Wilmington 241
Cambridge 227
Ann Arbor 207
Boardman 145
Dearborn 115
Jacksonville 98
Princeton 76
Dublin 73
Beijing 72
Dong Ket 64
Udine 51
New York 49
San Diego 39
Washington 34
Brussels 29
Izmir 27
Los Angeles 26
Martignacco 26
Redmond 26
Brno 25
Ogden 24
Dallas 22
Des Moines 21
Munich 20
Zurich 15
Phoenix 13
Falls Church 12
Guangzhou 12
Helsinki 12
Nanjing 12
Norwalk 12
Hyderabad 11
Milan 11
Leawood 10
Naples 10
Trieste 10
Arezzo 9
London 9
Santa Clara 9
Timisoara 9
Vienna 9
Frankfurt am Main 8
Hefei 8
Augusta 7
Jinan 7
Nuremberg 7
Rome 6
Warsaw 6
Belluno 5
Codroipo 5
Cordenons 5
Genoa 5
Hong Kong 5
Jiaxing 5
Kunming 5
Nanchang 5
Scafati 5
Shanghai 5
Simi Valley 5
Toronto 5
Ardabil 4
Bovisio-Masciago 4
Edinburgh 4
Fuzhou 4
Lappeenranta 4
Lomé 4
Menlo Park 4
Ottawa 4
Paris 4
Redwood City 4
Shenzhen 4
Tallinn 4
Tokyo 4
Wuhan 4
Zoppola 4
Cairo 3
Caserta 3
Grafing 3
Hebei 3
Montréal 3
Münster 3
Nutley 3
Porcia 3
Prague 3
San Mateo 3
Shenyang 3
São Paulo 3
Treviso 3
Amsterdam 2
Bologna 2
Castelfranco Veneto 2
Cavaso del Tomba 2
Changsha 2
Totale 4.978
Nome #
In patients with metastatic breast cancer the identification of circulating tumor cells in epithelial-to-mesenchymal transition is associated with a poor prognosis 179
Neutrophil-to-lymphocyte and lymphocyte-to-monocyte ratios in breast cancer 144
MGMT pyrosequencing-based cut-off methylation level and clinical outcome in patients with glioblastoma multiforme 141
First steps in the definition of a prognostic score based on MGMT methylation status in patients with glioblastoma 136
Luminal-like HER2-negative stage IA breast cancer: A multicenter retrospective study on long-term outcome with propensity score analysis 134
Pattern of metastasis and outcome in patients with breast cancer 132
The SLICE study: The prognostic role of visceral fat in metastatic colorectal cancer 128
Treatment of metastatic breast cancer in a real-world scenario: Is progression-free survival with first line predictive of benefit from second and later lines? 124
Defining a prognostic score based on O6-methylguanine-DNA methyltransferase cut-off methylation level determined by pyrosequencing in patients with glioblastoma multiforme 120
Caring for cancer survivors: perspectives of oncologists, general practitioners and patients in Italy 119
Emerging Role of Genomics and Cell-Free DNA in Breast Cancer 119
Third-generation tyrosine kinase inhibitor in the treatment of epidermal growth factor receptor mutated squamous cell lung cancer: a tailored therapy approach 118
Androgen receptor in estrogen receptor positive breast cancer: Beyond expression 115
Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype 114
Measures of outcome in metastatic breast cancer: insights from a real-world scenario. 112
Real-time tests of multiple genome alterations take the first steps into the clinic: a learning example 112
Comparison of primary breast cancer and paired metastases: biomarkers discordance influence on outcome and therapy 107
Prognostic role of disease extent and lymphocyte-monocyte ratio in advanced melanoma 107
Lactate Dehydrogenase (LDH) Response to First-Line Treatment Predicts Survival in Metastatic Breast Cancer: First Clues for A Cost-Effective and Dynamic Biomarker 106
Do platinum salts fit all triple negative breast cancers? 104
Role of Bruton's Tyrosine Kinase in Stage III Colorectal Cancer 102
Determinants of Last-line Treatment in Metastatic Breast Cancer 101
APE1 and NPM1 protect cancer cells from platinum compounds cytotoxicity and their expression pattern has a prognostic value in TNBC 99
Controversies in monitoring metastatic breast cancer during systemic treatment. Results of a GIM (Gruppo Italiano Mammella) survey 98
The role of sidedness in second-line therapy for RAS wild-type colorectal cancer: a network meta-analysis (NMA) 97
Prognostic role of disease extent and lymphocyte-monocyte ratio in advanced melanoma 97
The IMPACT study: early loss of skeletal muscle mass in advanced pancreatic cancer patients 96
Pertuzumab and breast cancer: another piece in the anti-HER2 puzzle 95
Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study 95
Mucosal Injury during Anti-Cancer Treatment: From Pathobiology to Bedside 95
Factors affecting patient's perception of anticancer treatments side-effects: an observational study. 94
Selecting patients for gastrectomy in metastatic esophago-gastric cancer: Clinics and pathology are not enough 94
Complementary and alternative medicine in oncology [Le terapie alternative e complementari in oncologia] 93
Circulating tumor DNA analysis in breast cancer: Is it ready for prime-time? 93
KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC 91
Outcomes of advanced gastric cancer patients treated with at least three lines of systemic chemotherapy 87
A risk score integrating lymphocytes ratios (LRs) and lactate dehydrogenase (LDH) levels to predict prognosis in metastatic breast cancer (MBC) patients 87
Monocyte-to-lymphocyte ratio in metastatic colorectal cancer: Prognostic role evaluation and cut-off definition 86
Tumour-infiltrating lymphocytes, programmed death ligand 1 and cyclooxygenase-2 expression in skin melanoma of elderly patients: clinicopathological correlations. 84
null 84
Platinum Salts in Patients with Breast Cancer: A Focus on Predictive Factors 84
Association of a novel circulating tumor DNA next-generating sequencing platform with circulating tumor cells (CTCs) and CTC clusters in metastatic breast cancer 83
Risk factors and survival outcomes in patients with brain metastases from breast cancer 80
Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: A propensity score analysis 80
The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper 75
Monitoring metastatic breast cancer (M-MBC) during treatment: a GIM (Gruppo Italiano Mammella) survey 74
Post-neoadjuvant strategies in breast cancer: From risk assessment to treatment escalation 73
Low dose CT scan screening versus empiric surveillance in asbestos exposed subjects: Update of ATOM 002 study 72
Neutrophil-to-lymphocyte ratio in metastatic breast cancer patients: relationship with tumor characteristics and survival 71
Hype or hope? The strange case of platinum salts’ renaissance in breast cancer 69
Plasma-Based Longitudinal Evaluation of ESR1 Epigenetic Status in Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer 69
Small luminal-like breast cancer: determinants of adjuvant chemotherapy use 68
Bevacizumab or PARP-Inhibitors maintenance therapy for platinum-sensitive recurrent ovarian cancer: A network meta-analysis 63
Use and perception of complementary and alternative medicine among cancer patients: the CAMEO-PRO study: Complementary and alternative medicine in oncology 59
Homophilic CD44 interactions mediate tumor cell aggregation and polyclonal metastasis in patient-derived breast cancer models 58
KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic non-squamous NSCLC 58
Performance of a novel Next Generation Sequencing circulating tumor DNA (ctDNA) platform for the evaluation of samples from patients with metastatic breast cancer (MBC) 57
CDKN1B mutation and copy number variation are associated with tumor aggressiveness in luminal breast cancer 57
Biologically driven cut-off definition of lymphocyte ratios in metastatic breast cancer and association with exosomal subpopulations and prognosis 55
Longitudinal dynamics of circulating tumor cells and circulating tumor DNA for treatment monitoring in metastatic breast cancer 55
Time to surgery after neoadjuvant chemotherapy for early breast cancer 53
Circulating tumor cell clusters are frequently detected in women with early-stage breast cancer 53
The curious phenomenon of dual-positive circulating cells: Longtime overlooked tumor cells 52
Image Analysis of Circulating Tumor Cells and Leukocytes Predicts Survival and Metastatic Pattern in Breast Cancer Patients 50
1781P Feasibility of an automated data solution for Binary Alignment Map (BAM) files generated through next generation sequencing (NGS) of circulating tumor DNA (ctDNA) 47
The MIMIC Study: Prognostic Role and Cutoff Definition of Monocyte-to-Lymphocyte Ratio and Lactate Dehydrogenase Levels in Metastatic Colorectal Cancer 47
Lactate dehydrogenase as a prognostic biomarker in patients with hormone receptor-positive metastatic breast cancer treated with palbociclib: An exploratory cohort study 47
Is ctDNA ready to outpace imaging in monitoring early and advanced breast cancer? 43
Determinants of choice in offering drug holidays during first-line therapy for metastatic colorectal cancer 40
A new dried blood spot LC-MS/MS method for therapeutic drug monitoring of palbociclib, ribociclib, and letrozole in patients with cancer 39
Prognostic role of visceral fat for overall survival in metastatic colorectal cancer: A pilot study 38
Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer 38
An Integrated Pharmacological Counselling Approach to Guide Decision-Making in the Treatment with CDK4/6 Inhibitors for Metastatic Breast Cancer 37
Clinico-radiological monitoring strategies in patients with metastatic breast cancer: a real-world study 37
Association of ADME gene polymorphisms on toxicity to CDK4/6 inhibitors in patients with HR+ HER2- metastatic breast cancer 35
Clinical impact of body mass index on palbociclib treatment outcomes and effect on exposure 33
BET proteins regulate homologous recombination-mediated DNA repair: BRCAness and implications for cancer therapy 33
Therapeutic Monitoring of Palbociclib, Ribociclib, Abemaciclib, M2, M20, and Letrozole in Human Plasma: A Novel LC-MS/MS Method 30
Landscape of circulating tumour DNA in metastatic breast cancer 28
Understanding the organ tropism of metastatic breast cancer through the combination of liquid biopsy tools 26
Cellular residual disease (CRD) in early breast cancer –Expanding the concept of minimal residual disease monitoring? 26
Tailoring adjuvant endocrine therapy in early breast cancer: When, how, and how long? 25
Definition of High-Risk Early Hormone-Positive HER2−Negative Breast Cancer: A Consensus Review 25
Abstract PD10-01: Impact of ESR1 mutations on Selective Estrogen Receptor Degraders and Modulators: an integrated liquid-biopsy and pharmacodynamics approach 23
The use of liquid biopsy in early breast cancer: clinical evidence and future perspectives 23
Liquid Biopsy, an Everchanging Balance between Clinical Utility and Emerging Technologies 22
Oncotype DX results increase concordance in adjuvant chemotherapy recommendations for early-stage breast cancer 21
Unlocking the potential of Molecular Tumor Boards: from cutting-edge data interpretation to innovative clinical pathways 21
The use of serial circulating tumor DNA to detect resistance alterations in progressive metastatic breast cancer 21
First- and second-line treatment strategies for hormone-receptor (HR)-positive HER2-negative metastatic breast cancer: A real-world study 21
Impact of baseline and on-treatment glycemia on everolimus-exemestane efficacy in patients with hormone receptor-positive advanced breast cancer (EVERMET) 21
Body mass index impacts adverse events and drug plasma concentration: should dose intensity be included in the palbociclib equation? 17
Integrating machine learning-predicted circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) in metastatic breast cancer: A proof of principle study on endocrine resistance profiling 16
Circulating Tumor Cells Prediction in Hormone Receptor Positive HER2-Negative Advanced Breast Cancer: A Retrospective Analysis of the MONARCH 2 Trial 15
Integration of Cellular and Humoral Immune Responses as an Immunomonitoring Tool for SARS-CoV-2 Vaccination in Healthy and Fragile Subjects 13
A Phase II Single-arm Study of Palbociclib in Patients With HER2-positive Breast Cancer With Brain Metastases and Analysis of ctDNA in Patients With Active Brain Metastases 13
Optimizing CDK4/6 inhibitors in advanced HR+/HER2- breast cancer: A personalized approach 12
Quantification of Letrozole, Palbociclib, Ribociclib, Abemaciclib, and Metabolites in Volumetric Dried Blood Spots: Development and Validation of an LC-MS/MS Method for Therapeutic Drug Monitoring 12
Cell-free DNA comparative analysis of the genomic landscape of first-line hormone receptor-positive metastatic breast cancer from the US and China 12
Clinical Perspectives in the Use of Liquid Biopsy in Metastatic Breast Cancer 12
Totale 6.876
Categoria #
all - tutte 30.213
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 30.213


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020703 0 0 0 0 0 0 0 176 206 173 89 59
2020/20211.306 52 131 91 229 114 72 85 143 81 69 108 131
2021/2022753 88 69 15 14 14 40 46 25 20 107 221 94
2022/2023928 87 101 28 124 99 212 3 72 125 10 48 19
2023/2024715 45 29 56 30 118 193 9 19 43 25 30 118
2024/20251.065 130 158 97 110 189 121 175 85 0 0 0 0
Totale 7.033